04.02.2013 - European company and research leaders have urged EU heads to greenlight €80bn for Horizon2020.
The joint letter of the European Round Table of Industrialists (ERT) and European Research Council (ERC) arrived some days before the EU Council will decide over the proposed €80m R&D budget of the EU innovation programme from 2014-2020. „We call on Europe’s leaders to approve the €80bn funding programme for research and innovation, Horizon 2020. This will lay the foundations for growth in Europe“, said ERC chief Helga Nowotny and ERT head Leif Johansson. The stakeholders warned that „any reduction in the funding to support excellent research will result in Europe having limited means to attract outstanding talent in a highly competitive global market.“
The EU heads will meet this week after negotiations of the EU Summit last November failed. A week before Council President Hermann van Rompuy’s initial budget proposal was withdrawn, 44 Nobel laureates had already warned in about the consequences of budget cuts to research and innovation. Over 100,000 Internet users supported their call not to slash the European Research Council (ERC) budget for excellent fundamental research. However, initial ideas discussed by the heads of EU Member States at the end of November foresaw cutting the €80bn innovation programme’s proposed budget by 12% (about €10bn) or more in favour of agriculture and structural funds.
This time, the research lobbyists try to make a stronger case: “Industry has long realised that one of its most precious assets is people“, stressed Nowotny and Johansson. „A continued supply of well-trained scientists and entrepreneurs is essential, especially for SMEs and start-up companies. Europe’s future can only be built on its brains.“
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more